Your session is about to expire
← Back to Search
Study Summary
This trial tests the safety and effectiveness of a new injectable drug for knee pain caused by osteoarthritis.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have other health conditions that could make it difficult to evaluate the condition of your knee during the trial.You have pain near a joint that is not caused by osteoarthritis, such as pain from another condition or injury.You have certain conditions in your knee joint that make you ineligible for the study, such as osteonecrosis, severe arthritis, or knee pain caused by something other than arthritis.You have had allergic reactions to resiniferatoxin (RTX) or similar substances like capsaicin found in chili peppers.You have tried the standard treatment for your pain before, but it didn't work well enough for you.
- Group 1: RTX-GRT7039
- Group 2: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any open opportunities for volunteers to join this clinical research?
"Confirmed, this medical trial is still recruiting participants. Clinicaltrials.gov states the study's initial posting was on August 26th 2022 and the last update was February 23rd 2023."
How likely are adverse effects for those taking RTX-GRT7039?
"Our team at Power evaluated RTX-GRT7039's safety as a 3, given that there are sufficient clinical trials to demonstrate its efficacy and multiple studies showing it is safe."
How many medical institutions are offering this research experiment?
"Currently, Aggarwal and Associates Limited in Brampton, Malton Medical Research in Mississauga, Diex Research Sherbrooke Inc. in Sherbrooke are all participating sites for this ongoing trial with an additional 4 locations also actively recruiting patients."
How many participants have been recruited for this research endeavor?
"To properly conduct this clinical trial, an aggregate total of 450 qualified individuals must be enrolled. Patients are able to participate from two sites in the provinces of Ontario and Quebec; Aggarwal and Associates Limited located in Brampton and Malton Medical Research situated in Mississauga."
Share this study with friends
Copy Link
Messenger